Summary of NACI statement of May 17, 2024: Statement on the prevention of respiratory syncytial virus disease in infants

Download in PDF format
(356 KB, 6 pages)

Organization: Public Health Agency of Canada

Date published: 2024-05-17

Cat.: HP40-355/2-2024E-PDF

ISSN: 978-0-660-71102-7

Pub.: 240020

On this page


Following a thorough review of the evidence provided by nirsevimab and RSVpreF, NACI makes the following recommendations for public health and individual decision-making:

NACI will continue to monitor the evolving evidence and will update guidance as needed.

For more information on which groups are considered to be at increased risk of severe RSV disease, please see List 1 in the NACI statement.

For the full statement, including supporting evidence, rationale, and a list of infants considered to be at increased risk of severe RSV disease, please see NACI's statement on the prevention of RSV disease in infants.

What you need to know

For more information on NACI's recommendations on the use of RSV immunization for infants, please refer to the RSV chapter in the Canadian Immunization Guide (CIG), as well as additional statements on the NACI web page.


"NACI's new recommendation to build toward a universal RSV immunization program will create more opportunities to protect infants against severe RSV disease. We recognize that moving towards this goal will take time and that it will involve implementing change across many levels of our health care system. However, we strongly believe that a universal RSV program will have a significant impact on the health of infants. NACI encourages people to discuss available immunization options in their setting with a healthcare provider in advance of childbirth. NACI's recommendations are grounded in the best available scientific evidence. We will update our guidance as needed, as evidence continues to accumulate and as advancements are made on the best ways to protect infants."

Dr. Robyn Harrison, NACI Chair

"Respiratory syncytial virus (RSV) is one of the most common respiratory viruses in infants and young children, infecting almost all children by two years of age. Severe RSV disease is most common in young infants in their first months of life during the RSV season, generally from late fall to early spring. Canada has two new options to help protect infants against severe RSV disease – Beyfortus (nirsevimab) and Abrysvo (RSVpreF). NACI's new guidance provides a foundation for a future universal immunization program for all infants. Moving toward a universal RSV program will provide an additional tool to protect infants in Canada during the respiratory virus season, when influenza and COVID-19 can also co-circulate in our communities and contribute to stress on our healthcare systems. I thank NACI for continuing to provide timely, expert advice to help protect the health of people in Canada."

Dr. Theresa Tam, Chief Public Health Officer

Page details

Date modified: